Comorbidities of COVID-19 patients associated with mortality at the Baubau Regional Public Hospital, South East Sulawesi

https://doi.org/10.19106/JMedSci005503202305

Evi Mustiqawati(1*), Sri Yolandari(2), Ratih Nurwanti(3), Sapril Sapril(4)

(1) Department of Pharmacy, Baubau Polytechnic, South East Sulawesi
(2) Department of Pharmacy, Baubau Polytechnic, South East Sulawesi
(3) Department of Pharmacy, Baubau Polytechnic, South East Sulawesi
(4) Department of Pharmacy, Baubau Polytechnic, South East Sulawesi
(*) Corresponding Author

Abstract


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that cause coronavirus disease 2019 (COVID-19) has become a global pandemic. Until November 30th, 2020, World Health Organization (WHO) confirmed 61,869,330 positive cases with 1,448,896 deaths (CFR 2.3%). Some comorbidities are associated with the COVID-19 mortality. This study aimed to investigate risk factors of the COVID-19 mortality at the Baubau Regional Public Hospital, Sout East Sulawesi. It was a cross-sectional study with a retrospective analysis involving 81 COVID-19 patients. Purposive sampling was applied in this study. Chi-square analysis was conducted to calculate odd ratio (OR). The result showed that in the period from January to September 2021, 30 COVID-19 patients died consisting of 20 male and 10 female. Most of the patients died were >45 yo and only 4 patients died were <45 yo. Among the patients died, 11 patients had hypertension, 12 patients had type 2 diabetes mellitus (DM), 4 patients had pulmonary TB and 3 patients had dyspepsia. Further analysis showed that hypertension (OR=6.803; 95%CI: 1.925-24.038; p=0.002) and dyspepsia (OR=0.222; 95%CI: 0.059-0.838; p=0.016) were significantly associated with the COVID-19 mortality, whereas type 2 DM (OR=1.123; 95%CI: 0.445-2.832; p=0.495) and pulmonary TB (OR=0.559; 95%CI: 0.059-0.838; p=0.270) were not. In conclusion, hypertension is risk factor, whereas dyspepsia is protective factor of COVID-19 mortality.


Keywords


Analysis of Mortality Risk Factors in Covid-19

Full Text:

PDF


References


1.Luo L, Fu M, Li Y, Hu S, Luo J, Chen Z, et al. The potential association between common comorbidities and severity and mortality of Coronavirus disease 2019: a pooled analysis. Clin Cardiol 2020; 43(12):1478-93.
https://doi.org/10.1002/clc.23465
2.Tisminetzky M, Delude C, Hebert T, Carr C, Goldberg RJ, Gurwitz JH. Age, multiple chronic conditions, and COVID-19: a literature review. J Gerontol A Biol Sci Med Sci 2022; 77(4):872-8.
https://doi.org/10.1093/gerona/glaa320
3.Ibadurrohman R. Decree Minister Health Republic Indonesia Number Hk.01.07/Menkes/413/2020 concerning Guidelines for the Prevention and Control of Coronavirus Disease 2019 (COVID-19). Office of Assistant to Deputy Cabinet Secretary for State Documents & Translation. https://setkab.go.id/en/health-ministry-issues-new-guidelines-on-covid-19-handling/. Jakarta. (25 November 2021).
4.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5
5.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507-13.
https://doi.org/10.1016/S0140-6736(20)30211-7
6.Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 2020; 133(9):1025-31.
https://doi.org/10.1097/CM9.0000000000000744
7.Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4):420-22.
https://doi.org/10.1016/S2213-2600(20)30076-X
8.Satuan Penanganan Covid-19. National COVID-19 handling task force. Spread Map. https://doi.org/covid19.go.id/peta-sebaran. (2 Agustus 2021).
9.Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18):1708-20.
htpps://doi.org/10.1056/NEJMoa2002032.
10.Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46(5):846-8.
https://doi.org/10.1007/s00134-020-05991-x.
11.Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis 2021;31(3):745-55.
https://doi.org/10.1016/j.numecd.2020.12.009.
12.Mirza H, Noori MAM, Akbar H, Fichadiya H, Kaur IP, Sachdeva S, et al. Hypertension as an independent risk factor for in-patient mortality in hospitalized COVID-19 patients: a multicenter study. Cureus 2022;14(7):e26741.
htpps://doi.org/10.7759/cureus.26741.
13.Ganguli S, Howlader S, Dey K, Barua S, Islam MN, Aquib TI, et al. Association of comorbidities with the COVID-19 severity and hospitalization: a study among the recovered individuals in Bangladesh. Int J Health Sci (Qassim). 2022;16(4):30-45.
14.Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of hypertension on the severity of COVID-19: a review. J Cardiovasc Pharmacol 2021;78(5):e648-55.
https://doi.org/10.1097/FJC.0000000000001116.
15.Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382(17):1653-59.
https://doi.org/10.1056/NEJMsr2005760
16.Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of hypertension on the severity of COVID-19: a review. J Cardiovasc Pharmacol 2021; 78(5):e648-55.
https://doi.org/10.1097/FJC.0000000000001116.
17.Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res 2020; 43(10):1028-46.
https://doi.org/10.1038/s41440-020-0515-0
18.Rucker AJ, Rudemiller NP, Crowley SD. Salt, hypertension, and immunity. Annu Rev Physiol 2018;80: 283–307.
http://doi.org/doi: 10.1146/annurev-physiol-021317-121134.
19.Rodríguez-Iturbe B, Pons H, Quiroz Y, et al. Autoimmunity in the pathogenesis of hypertension. Nat Rev Nephrol 2014; 10:56–62.
https://doi.org/doi: 10.1038/nrneph.2013.248.
20.Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol 2021;33(5):419-30.
https://doi.org/10.1097/BOR.0000000000000822.
21.Oshima T, Siah KTH, Yoshimoto T, Miura K, Tomita T, Fukui H, et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: a population-based survey. J Gastroenterol Hepatol 2021; 36(7):1820-7.
https://doi.org/10.1111/jgh.15346
22.Oliviero G, Ruggiero L, D'Antonio E, Gagliardi M, Nunziata R, Di Sarno A, et al. Impact of COVID-19 lockdown on symptoms in patients with functional gastrointestinal disorders: relationship with anxiety and perceived stress. Neurogastroenterol Motil 2021; 33(5):e14092.
https://doi.org/doi: 10.1111/nmo.14092



DOI: https://doi.org/10.19106/JMedSci005503202305

Article Metrics

Abstract views : 542 | views : 388


Bookmark and Share


Copyright (c) 2023 Evi Mustiqawati, Sri Yolandari, Ratih Nurwanti, Sapril

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.